Nancy Hey - Evidence informed policy making - 26 June 2017OECD Governance
Presentation by Nancy Hey, Director What Works Centre for Wellbeing, United Kingdom, at the event on Governing better through evidence-informed policy making, 26-27 June 2017. The event was organised by the OECD Directorate for Public Governance in cooperation with the European Commission’s Joint Research Centre (JRC), the Campbell Collaboration and the International Network for Government Science Advice (INGSA). For further information please see http://www.oecd.org/gov/evidence-informed-policy-making.htm
Stephan Fraser - Evidence informed policy making - 27 June 2017OECD Governance
Presentation by Stephen Fraser, Director International Partnerships, The Education Endowment Foundation, United Kingdom, at the event on Governing better through evidence-informed policy making, 26-27 June 2017. The event was organised by the OECD Directorate for Public Governance in cooperation with the European Commission’s Joint Research Centre (JRC), the Campbell Collaboration and the International Network for Government Science Advice (INGSA). For further information please see http://www.oecd.org/gov/evidence-informed-policy-making.htm
Christopher L. Griffin - Evidence informed policy making - 26 June 2017OECD Governance
Presentation by Christopher L. Griffin, Research Director, Access to Justice Lab, Harvard Law School, at the event on Governing better through evidence-informed policy making, 26-27 June 2017. The event was organised by the OECD Directorate for Public Governance in cooperation with the European Commission’s Joint Research Centre (JRC), the Campbell Collaboration and the International Network for Government Science Advice (INGSA). For further information please see http://www.oecd.org/gov/evidence-informed-policy-making.htm
Future Flight Fridays: Public trust - social science considerationsKTN
Slides from KTN's recent Future Flight Fridays session exploring some of the wider social concerns around Future flight and the priorities we need to consider in order to realise the 2030 vision for future flight in the UK.
UUK AHSN discussion - higher education and health researchtomlyscom
Universities are an indispensible part of the UK’s healthcare system. Their contribution is wide-ranging; universities sustain and enrich our health services not only by supplying and developing the healthcare workforce but also by operating as the crucibles for service innovation and excellence.
What role do universities play in health research and how are they placed to be involved in AHSNs?
What shape should AHSNs take and what might an ‘ideal’ AHSN look like?
What steps can we take to get there?
Nhs innovation accelerator understanding how and why the nhs adopts innovationHugh Risebrow
Thanks Nael Clarke for highlighting Wessex AHSN report on adoption of innovation in the NHS. Innovation is difficult in any organisation, but why is it so much harder in the NHS than in say Apple, Amazon or most private businesses: My views:
1. Organisational success. In private b2c companies, success results from attracting and retaining customers through delivering innovative services which meet their needs better than competition. In the NHS, success is much more about achieving arbitrary political targets, and patients have limited choice.
2. Organisational incentives. Many innovative companies set divisional objectives around the proportion of income from new products.
3. Individual and team incentives. In successful b2c businesses, financial and career recognition/ promotion rewards are often linked to innovation. There is recognition that innovation may need a few reiterations to succeed. In the NHS, few get fired for preserving the status quo, but many lose out of they innovate and it fails first time round, and there are no individual or team incentives.
Many in the NHS seek to innovate in order to deliver better care at a lower cost. They are often faced with organisational resistance or at least inertia, and excessive bureaucracy.
Lesson 101 in management s that you get the behaviours that you incentivise. (How) should the NHS change the incentives? Is there scope for more NHS owned 'spin-outs' which allow private sector type financial incentives for staff, and greater freedom from NHS bureaucracy and governance?
Nancy Hey - Evidence informed policy making - 26 June 2017OECD Governance
Presentation by Nancy Hey, Director What Works Centre for Wellbeing, United Kingdom, at the event on Governing better through evidence-informed policy making, 26-27 June 2017. The event was organised by the OECD Directorate for Public Governance in cooperation with the European Commission’s Joint Research Centre (JRC), the Campbell Collaboration and the International Network for Government Science Advice (INGSA). For further information please see http://www.oecd.org/gov/evidence-informed-policy-making.htm
Stephan Fraser - Evidence informed policy making - 27 June 2017OECD Governance
Presentation by Stephen Fraser, Director International Partnerships, The Education Endowment Foundation, United Kingdom, at the event on Governing better through evidence-informed policy making, 26-27 June 2017. The event was organised by the OECD Directorate for Public Governance in cooperation with the European Commission’s Joint Research Centre (JRC), the Campbell Collaboration and the International Network for Government Science Advice (INGSA). For further information please see http://www.oecd.org/gov/evidence-informed-policy-making.htm
Christopher L. Griffin - Evidence informed policy making - 26 June 2017OECD Governance
Presentation by Christopher L. Griffin, Research Director, Access to Justice Lab, Harvard Law School, at the event on Governing better through evidence-informed policy making, 26-27 June 2017. The event was organised by the OECD Directorate for Public Governance in cooperation with the European Commission’s Joint Research Centre (JRC), the Campbell Collaboration and the International Network for Government Science Advice (INGSA). For further information please see http://www.oecd.org/gov/evidence-informed-policy-making.htm
Future Flight Fridays: Public trust - social science considerationsKTN
Slides from KTN's recent Future Flight Fridays session exploring some of the wider social concerns around Future flight and the priorities we need to consider in order to realise the 2030 vision for future flight in the UK.
UUK AHSN discussion - higher education and health researchtomlyscom
Universities are an indispensible part of the UK’s healthcare system. Their contribution is wide-ranging; universities sustain and enrich our health services not only by supplying and developing the healthcare workforce but also by operating as the crucibles for service innovation and excellence.
What role do universities play in health research and how are they placed to be involved in AHSNs?
What shape should AHSNs take and what might an ‘ideal’ AHSN look like?
What steps can we take to get there?
Nhs innovation accelerator understanding how and why the nhs adopts innovationHugh Risebrow
Thanks Nael Clarke for highlighting Wessex AHSN report on adoption of innovation in the NHS. Innovation is difficult in any organisation, but why is it so much harder in the NHS than in say Apple, Amazon or most private businesses: My views:
1. Organisational success. In private b2c companies, success results from attracting and retaining customers through delivering innovative services which meet their needs better than competition. In the NHS, success is much more about achieving arbitrary political targets, and patients have limited choice.
2. Organisational incentives. Many innovative companies set divisional objectives around the proportion of income from new products.
3. Individual and team incentives. In successful b2c businesses, financial and career recognition/ promotion rewards are often linked to innovation. There is recognition that innovation may need a few reiterations to succeed. In the NHS, few get fired for preserving the status quo, but many lose out of they innovate and it fails first time round, and there are no individual or team incentives.
Many in the NHS seek to innovate in order to deliver better care at a lower cost. They are often faced with organisational resistance or at least inertia, and excessive bureaucracy.
Lesson 101 in management s that you get the behaviours that you incentivise. (How) should the NHS change the incentives? Is there scope for more NHS owned 'spin-outs' which allow private sector type financial incentives for staff, and greater freedom from NHS bureaucracy and governance?
Academic Health Science Networks supporting strategic commissioningInnovation Agency
Dr Liz Mear, Chief Executive of the Innovation Agency, presented at NHS Confed 17 on Academic Health Science Networks (AHSNs) supporting strategic commissioning and bringing innovators, commissioners, clinicians and patients to together to develop closer collaboration and a demonstrably clearer understanding of NHS needs and opportunities.
Let us share with you our successes, impacts and performance over the past year. The Innovation Agency is proud to bring you our Annual Report for 2015/16.
Dr Liz Mear, Chief Executive of the Innovation Agency presented at NHS Confed 17 about the NHS’ role in growing local economies and how Academic Health and Science Networks (AHSNs) can generate economic growth in life sciences through their role as catalysts, connectors and collaborators by spreading innovation, advancing health technology and improving healthcare
Jon Bisson NISCHR - Looking to the futureangewatkins
Community Nursing Research Strategy Masterclass
13th September 2013
The WSPCR was requested to organise a research masterclass for the Directors of Nursing from all the Welsh Health Boards on Friday 11th Sept. It was funded by the Health Minister and attended by the CNO. It also included the Head of the NISCHR and the manager of AHSC. The masterclass included the presentation of the Welsh Community Nurse Research Strategy which aims to raise the quality and quantity of research in Community Nursing in Wales. The workshop also generated further areas for research activity/priority.
http://www.wspcr.ac.uk/crns-masterclass-sep-2013.php
5th international congress on healthcare and hospital managementNadeem Baig
5th INTERNATIONAL CONGRESS ON HEALTHCARE AND HOSPITAL MANAGEMENT
“Innovation in Healthcare Services, Lean Management and Technological Developments”
10 -13 December 2014
www.hsyk-antalya.org
Spice Hotels & SPA, Belek, Antalya
Day 1: Challenges and opportunities for better detection, diagnosis and clini...KTN
The focus of this session is to explore how the UK health system is currently responding to the increasing number of patients with multiple long-term conditions and the impacts of healthcare inequalities on patient outcomes. We will also explore opportunities for businesses to bring about much needed innovations in the prevention, early diagnosis and management of multi-morbidity.
The Clinical and Translational Science Awards (CTSA) Program: What can it do ...CTSciNet .org
Meeting: Physician-Scientist Career Development Meeting, New York Academy of Sciences, November 3-5, 2010
Panel: Successful Strategies for the Physician-Scientist
Presentation: The Clinical and Translational Science Awards (CTSA) Program: What can it do for you?
Speaker: Lisa Guay-Woodford, M.D., Professor and Vice Chair of Genetics, CTSA director, University of Alabama, Birmingham
View online with audio at http://community.sciencecareers.org/ctscinet/groups/sessions/2010/12/the-ctsa-program.php
The 2016 Impact Report – Improving Health and Promoting Economic Growth has been published today (13 June 2016) by the national Academic Health Science Network (AHSN) and outlines the work done by its 15 members over the last 12 months. The report outlines achievements by individual AHSNs , and where the different organisations have worked in partnership.
This is the impact report which outlines the collective impact each AHSN had both individually and collaboratively in 2015-16. The report features key forewords from national leaders and many case studies showing where the work of AHSNs is having a real impact in the health system, and therefore, on people's lives.
Similar to Rachel Munton (AHSN Network) Working with Academic Health Science Networks hcs15 (20)
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
the IUA Administrative Board and General Assembly meeting
Rachel Munton (AHSN Network) Working with Academic Health Science Networks hcs15
1. Working with Academic
Health Science Networks:
Translating Innovation into
Practice
Professor Rachel Munton, Managing
Director
#HCS15 Healthcare Scientists – Making it
Happen
Monday 16 March 2015
2. Aims for the day
To inform and support healthcare
scientists to look up and out
To engage with the new and evolving
structures of the NHS
To help set and define the agenda for the
year to come.
4. How AHSNs make a difference
We connect: bringing together academics, NHS,
researchers and industry to accelerate innovation and
facilitate the adoption and spread of proven ideas.
We are catalysts: helping facilitate change across
whole health and social care economies - with a focus
on improving outcomes for patients.
We create the right environment for relevant industries
to work with the NHS and other parts of the healthcare
sector.
5. AHSN Four key objectives
Build a culture of
partnership,
collaboration,
inclusivity in
addressing local
and national
priorities
Create wealth
through co-
development,
testing, evaluation
and adoption of
new products and
services
Speed up
adoption of
innovation to
improve clinical
outcomes and
patient
experience
Focus on needs
of patients and
local
populations,
promoting
health equality
6. About AHSNs
The diversity of AHSN priorities reflects the many
challenges of improving health and wealth in each
region.
However all 15 share a focus on:
Promoting economic growth [e.g. SBRI programme]
Diffusing innovation and putting proven research into
practice
Improving patient safety
Improving quality and reducing variation
Optimising medicine use
7. Are patient-focussed with a clear focus on the needs and
challenges of the patients and populations they serve – with a
commitment to driving forward quality
Have a fundamental cultural of collaboration, working in
multidisciplinary teams, across organisational boundaries and
with industry colleagues
Work at the cutting edge of technology, analysing and rolling
out developments across the NHS, guiding others through the
landscape of the system
Are entrepreneurial and innovative, identifying gaps in provision
Work with industry and academia to bring new developments to
commercial fruition
About Healthcare Scientists
8. The Healthcare Science profession is central to the
step change in innovation and service provision
that is fundamental to the delivery of the Five Year
Forward View for the NHS and, more broadly, in
cementing this country’s status as a world leader in
the life sciences industry.
Healthcare scientists develop and deliver the
science and new technology necessary to
transform outcomes and they provide the essential
link between scientific and technological advances
and front line services, with a necessary role in the
earlier diagnosis and prevention agenda.
HCS & AHSNs: a shared
agenda?
9. Creation
• new things
• new ideas
• new techniques
• new approaches
Assessment
• new things
• new ideas
• new techniques
• new approaches
Uptake
• new things
• new ideas
• new techniques
• new approaches
Spread
• new things
• new ideas
• new techniques
• new approaches
Basic Research
Applied
Research
Commissioning Patient Care
• Better Quality
• Better Value
•Health and Wealth
NIHR
NHS
Commissioners
MRC & others
incl Charities
Providers of NHS
services
Working across the Innovation Pathway
INVENTION EVALUATION ADOPTION DIFFUSION
10. EMAHSN:
Transforming the health of
4.5m East Midlands
residents and stimulating
wealth creation
Name: Rachel Munton
Phone: 0115 8231300
Email: rachel.munton@nottingham.ac.uk
www.emahsn.org.uk
@EM_AHSN
@RachelMunton
